# Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery

> **NCT01547728** · PHASE4 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 42 (actual)

## Conditions studied

- Thrombophilia Due to Acquired Antithrombin III Deficiency

## Interventions

- **DRUG:** Recombinant antithrombin (rhAT)

## Key facts

- **NCT ID:** NCT01547728
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Too many barriers to enroll participants.
- **Last updated:** 2015-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01547728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01547728, "Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01547728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*